Favourable effect of safinamide on mood over 2-year treatment of fluctuating Parkinson’s disease patients

Objective: Safinamide (Xadago®, Zambon SpA, Italy), a new drug with dopaminergic and non-dopaminergic actions, was studied in late stage PD patients in two double-blind, placebo-controlled trials (016 and 018), showing an increase in “ON” time without increasing troublesome dyskinesia. The objective of this post-hoc analysis of studies 016 and 018 is to evaluate the efficacy of safinamide (100 mg/day oral tablets) vs placebo on mood in fluctuating PD patients over 2-year treatment.